• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Doubling the Odds: Two-Pronged Strategy to Halt Cancer Cell Proliferation

by Bellbrook Labs / Wednesday, 29 November 2017 / Published in HTS Assays, News, Uncategorized

It would be difficult to underestimate the importance of polo-like kinase 1 (Plk1) for cancer, given its influence on cell division. As one of five members of the Polo-like family of serine/threonine protein kinases in eukaryotic cells, Plk1 plays a multifaceted role in the cell cycle and thus controls cancer progression fueled by unchecked cell proliferation. It regulates mitotic entry and the G2/M checkpoint, coordinates the assembly of the centrosome and thus dictates timing of cell cycles, regulates the assembly of the mitotic spindle and chromosome segregation, plays key roles at the spindle midzone and during abscission, facilitates DNA replication, and is involved in cytokinesis and meiosis.¹

Cancer requires efficient cell division; thus it is not surprising that Plk1 is up-regulated in many tumor cell types.² Nor is it surprising that Plk1 is viewed as a promising drug target for novel chemotherapeutics.³

What is, perhaps, surprising is a fascinating drug discovery strategy by Chen et al., who engaged in small molecule inhibitor screening using a rather unusual criteria: identifying compounds that both inhibited the kinase activity of Plk1, and blocked nuclear localization during S and G2 phases of mitosis.4

In a very real sense, this might be described (as the saying goes) as a “kill two birds with one stone” approach.

PLK1 Inhibitor Blog

Here’s how they did it: Plk1 protein has an N-terminal kinase domain, and a C-terminal Polo box domain. To be activated, Plk1 has to be phosphorylated by another kinase (such as Aurora A and its partner Bolo) at threonine-210 in its activation loop. This sets up a series of events in which Plk1 binds to different partners that are themselves phosphorylated by either CDK1 or Plk1; these interactions affect the localization patterns of Plk1 to the centrosome, nucleus, and cytoplasm during S and G2 phases of mitosis.4

Confused? Here’s the short version: to fuel mitosis (and therefore to fuel cancer), Plk1 has to retain both 1) kinase ability, and 2) its capacity to be in the right place at the right time during mitosis.

This begged the question: why not try to find a small molecule inhibitor that affects both of these capabilities?

This is precisely the approach of Chen et al., who first conducted in silico (computational) approaches to virtually screen a library of 200,000 compounds in order to identify those that were likely to form a hydrogen bond or electrostatic interaction with key nuclear localization signal (NLS) residues of Plk1, and to form a hydrogen bond with a critical residue for ATP binding, plus have high likelihood of good hydrophobic interaction with the binding sites.4

The result?  200,000 candidates were narrowed down to 95. These were further assessed by immunofluorescence and flow cytometry to determine ability to cause cell cycle arrest.4

By this means, 95 candidates were narrowed to one: inhibitor D110, which was more extensively analyzed for its effect on apoptosis and subcellular localization of Plk1.

It worked. ELISA data confirmed that D110 binds the ATP pocket and the nuclear localization site of Plk1.4 Exposing cultured tumor cells to D110 caused mitotic arrest.4 And treating HeLa cells with D110 induced formation of a monopolar spindle and affects nuclear localization of Plk1 during interphase, indicating that the compound inhibits the catalytic activity of Plk1 in vivo.4

Last but certainly not least, D110 could induce apoptosis of human tumor cells in vivo, suggesting its promise as a primary compound for anticancer drug development. It also showed excellent selectivity for Plk1 versus other Polo-like kinase families, suggesting that it could have lower risk of off-targeted effects4

Will D110 prove to be a compound that is suitable for therapeutic use? Time will tell. But in the meantime, this project is an outstanding example of a creative strategy to discover novel inhibitors for kinases, as well as the relevancy of small molecule kinase inhibitor discovery.

-Robyn M. Perrin, PhD

Learn More About the Transcreener Kinase Assay

References

[1] Zhixian L,Qingrong S,Xiaosheng W, 2017. Plk1, A Potential Target for Cancer Therapy. Transl Oncol. 10(1): 22–32.

[2] Gutteridge RE, Ndiaye MA, Liu X, Ahmad N. 2016. Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics. Mol Cancer Ther. 15(7):1427-35.

[3] Lee KS, Burke TR Jr, Park JE, Bang JK, Lee E. 2015. Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. Trends Pharmacol Sci. 36(12):858-77.

[4] Chen F, Zhuo X, Qin T, Guo X, Zhang C, Lai L. 2017. Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest. Chem Biol Drug Des. 89(5):732-740.

Tagged under: Assay Development Services, drug discovery services, kinase assay, Transcreener ADP Kinase Assay

What you can read next

BellBrook Labs Awarded NIH Grant to Validate New Target for Liver Fibrosis Using Transcreener GTPase Assay Platform
Minding the Membrane: Powerful Approach to Interrogate Molecular Events in Ras-PI3K Interactions
FUT7 Fucosyltransferase Assays and Chronic Inflammation
FUT7, Inflammation, and Fucosyltransferase Assays

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...
  • SIRT2 Affects Neurodegenerative Diseases

    SIRT2 Isoforms in Neurodegenerative Diseases & Cancer

    Silent information regulator type 2 (Sirtuin 2 ...
  • Patient With WRN Helicase Syndrome

    Can WRN Helicase Inhibitors Treat MSI-H Cancers?

    Over 100 years ago, Otto Werner first character...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP